Iradimed Corporation announced its financial results for the third quarter of 2026, reporting a record revenue of $24.2 million. This figure represents a $3.0 million increase, or 14%, compared to the same period in 2025. It also marks an increase of $3.7 million, or 18%, from the second quarter of 2026.
For the nine months ended September 30, 2026, total revenue was $66.6 million, up 9% from $61.1 million during the same period in 2025. The company reported GAAP diluted earnings per share of $0.51 for the third quarter, compared to $0.43 in the prior year, and non-GAAP diluted earnings per share of $0.55.
The company’s board of directors declared a regular quarterly cash dividend of $0.20 per share of common stock. The dividend is payable to stockholders of record as of the close of business on November 13, 2026, with a payment date of November 27, 2026.
Management provided updated guidance for the remainder of the year. For the fourth quarter of 2026, the company expects revenue of $25.0 million to $26.5 million. For the full year 2026, the company revised its revenue guidance to a range of $91.6 million to $93.1 million. The company also provided GAAP diluted EPS guidance of $1.90 to $1.94 for the full year and non-GAAP diluted EPS guidance of $2.07 to $2.11.
